{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"275.5","upperLimit":"2024","value":"746.9"},{"groupId":"OG001","lowerLimit":"784.5","upperLimit":"2041","value":"1265"},{"groupId":"OG002","lowerLimit":"1195","upperLimit":"2145","value":"1601"},{"groupId":"OG003","lowerLimit":"1425","upperLimit":"6454","value":"3032"},{"groupId":"OG004","lowerLimit":"111.8","upperLimit":"3595","value":"634.0"},{"groupId":"OG005","lowerLimit":"120.4","upperLimit":"740.6","value":"298.6"},{"groupId":"OG006","lowerLimit":"1535","upperLimit":"2915","value":"2115"},{"groupId":"OG007","lowerLimit":"1026","upperLimit":"2137","value":"1480"},{"groupId":"OG008","lowerLimit":"851.5","upperLimit":"2792","value":"1542"},{"groupId":"OG009","lowerLimit":"601.8","upperLimit":"1495","value":"948.4"}]}],"title":"Day 1 (n=6, 11, 36, 3, 3, 3, 24, 23, 17, 15)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"397.9","upperLimit":"1981","value":"887.9"},{"groupId":"OG001","lowerLimit":"611.5","upperLimit":"2232","value":"1168"},{"groupId":"OG002","lowerLimit":"918.9","upperLimit":"2018","value":"1362"},{"comment":"Data was not estimable if evaluable subjects were less than 3 as per the planned decision because only 2 collected values were not sufficient to calculate a reliable estimation.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Data was not estimable if evaluable subjects were less than 3 as per the planned decision because only 2 collected values were not sufficient to calculate a reliable estimation.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG005","lowerLimit":"56.10","upperLimit":"5150","value":"537.5"},{"groupId":"OG006","lowerLimit":"1696","upperLimit":"3368","value":"2390"},{"groupId":"OG007","lowerLimit":"922.1","upperLimit":"2239","value":"1437"},{"groupId":"OG008","lowerLimit":"543.4","upperLimit":"3431","value":"1365"},{"groupId":"OG009","lowerLimit":"636.9","upperLimit":"1811","value":"1074"}]}],"title":"Day 15 (n=6, 8, 25, 1, 1, 3, 17, 17, 10, 13)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"24"},{"groupId":"OG008","value":"18"},{"groupId":"OG009","value":"15"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"SAR245409 capsule administered at a single oral dose of 30 milligram (mg) on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG000","title":"SAR245409 30mg"},{"description":"SAR245409 capsule administered at a single oral dose of 50 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG001","title":"SAR245409 50mg"},{"description":"SAR245409 capsule administered at a single oral dose of 70 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG002","title":"SAR245409 70mg"},{"description":"SAR245409 capsule administered at a single oral dose of 90 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG003","title":"SAR245409 90mg"},{"description":"SAR245409 capsule administered twice, orally, at a dose of 30 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG004","title":"SAR245409 30mg Twice Daily"},{"description":"SAR245409 capsule administered twice, orally, at a dose of 50 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG005","title":"SAR245409 50mg Twice Daily"},{"description":"SAR245409 capsule administered at a single oral dose of 70 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG006","title":"TNBC: SAR245409 70mg Once Daily"},{"description":"SAR245409 capsule administered at a single oral dose of 70 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG007","title":"NSCLC: SAR245409 70mg Once Daily"},{"description":"SAR245409 capsule administered at a single oral dose of 70 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG008","title":"CRC: SAR245409 70mg Once Daily"},{"description":"SAR245409 capsule administered at a single oral dose of 70 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG009","title":"MEL: SAR245409 70mg Once Daily"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis set. Here \"n\" signifies the number of subjects evaluable at the specific time points.","reportingStatus":"POSTED","timeFrame":"Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts","title":"Area Under the Concentration-Time Curve (AUC) During a Dosing Interval (Tau) of SAR245409","type":"SECONDARY","unitOfMeasure":"hr*ng/mL"}